Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Surgery Partners (SGRY) Cost of Revenue (2016 - 2025)

Surgery Partners' Cost of Revenue history spans 12 years, with the latest figure at $730.9 million for Q4 2025.

  • For Q4 2025, Cost of Revenue rose 227.76% year-over-year to $730.9 million; the TTM value through Dec 2025 reached $878.9 million, up 29.59%, while the annual FY2025 figure was $878.9 million, 8.12% up from the prior year.
  • Cost of Revenue for Q4 2025 was $730.9 million at Surgery Partners, up from $49.0 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $730.9 million in Q4 2025 and bottomed at -$374.5 million in Q4 2023.
  • The 5-year median for Cost of Revenue is $172.5 million (2022), against an average of $134.5 million.
  • The largest annual shift saw Cost of Revenue plummeted 312.87% in 2021 before it surged 438.82% in 2022.
  • A 5-year view of Cost of Revenue shows it stood at -$332.5 million in 2021, then skyrocketed by 278.32% to $592.9 million in 2022, then crashed by 163.16% to -$374.5 million in 2023, then surged by 159.55% to $223.0 million in 2024, then surged by 227.76% to $730.9 million in 2025.
  • Per Business Quant, the three most recent readings for SGRY's Cost of Revenue are $730.9 million (Q4 2025), $49.0 million (Q3 2025), and $55.4 million (Q2 2025).